<DOC>
	<DOCNO>NCT00377988</DOCNO>
	<brief_summary>The purpose study use data health care information database ass risk venous thromboembolism ( blood clot ) , myocardial infarction ( heart attack ) , stroke among woman use transdermal contraceptive system ( ORTHO EVRA ) birth control compare woman use norgestimate-containing oral contraceptive 35 mcg ethinyl estradiol .</brief_summary>
	<brief_title>A Postmarketing Study Risk Venous Thromboembolism ( Blood Clots ) , Myocardial Infarction ( Heart Attacks ) , Stroke Among Women Using ORTHO EVRA ( Norelgestromin Ethinyl Estradiol Contraceptive Patch ) Compared With Women Who Take Oral Contraceptives Birth Control</brief_title>
	<detailed_description>ORTHO EVRA ( norelgestromin ethinyl estradiol ) once-a-week transdermal contraceptive ( birth control ) system small square-shaped patch worn body hormone patch absorb transdermally ( skin ) help prevent pregnancy . This observational case-control study use data provide United States health care claim database National Death Index ( NDI ) ass risk venous thromboembolism abbreviate VTE ( include deep vein thrombosis abbreviate DVT [ blood clot form one deep vein body , usually legs ] pulmonary embolism abbreviate PE [ blood clot lung ] ) , acute myocardial infarction abbreviate AMI ( heart attack ) , ischemic stroke ( blockage artery supply blood brain ) among woman use transdermal contraceptive system , ORTHO EVRA compare woman use norgestimate-containing oral contraceptive ( NGM-OCs ) 35 mcg ethinyl estradiol ( EE ) , period 01 April 2002 31 December 2004 extension period 01 January 2005 31 December 2006 . In extension period study ( 01 January 2005 31 December 2006 ) , mortality add endpoint study . After obtain Institutional Review Board ( IRB ) approval waiver authorization , request make medical record woman dispense least ORTHO EVRA NGM-OC whose health insurance claim consistent occurrence VTE , AMI , stroke . The primary outcome measure study AMI ischemic stroke combine current recent user ORTHO EVRA compare current recent user NGM-OCs 34 mcg EE . Observational study - No investigational drug administer . NOTE : The study conduct two part . Study CR014383 , NCT00511784 , represent first portion study . This study , CR012022 , represent second portion extend study .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Users transdermal contraceptive system norgestimatecontaining oral contraceptive 35 mcg ethinyl estradiol April 1 , 2002 December 31 , 2006 , identify Ingenix Research Database Have complete medical coverage pharmacy benefit Have claim associate physician service follow : malignancy nonmelanoma skin cancer coagulation defect , history venous thrombus/embolism , longterm anticoagulant use Chronic inflammatory disease</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hormonal contraception</keyword>
	<keyword>Oral contraception</keyword>
	<keyword>Ethinyl estradiol</keyword>
	<keyword>Progestin</keyword>
	<keyword>Transdermal</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Venous thromboembolism</keyword>
</DOC>